Yahoo Finance

Operations: The company generates revenue primarily from its Base USAP segment, totaling $611.71 million.

Market Cap: $50.58M

CarParts.com, with a market cap of US$50.58 million, remains unprofitable but has made strides in reducing losses over the past five years. The company is debt-free and its short-term assets of US$150.2 million comfortably cover both short and long-term liabilities. Recent initiatives include a partnership with Extend, enhancing customer satisfaction through shipping and product protection services. Despite high volatility in share price and no forecast for profitability within three years, CarParts.com trades at good value compared to peers while maintaining a stable cash runway that supports operations beyond one year without additional funding needs.

• Jump into the full analysis health report here for a deeper understanding of CarParts.com.

• Gain insights into CarParts.com's future direction by reviewing our growth report.

Taysha Gene Therapies

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Taysha Gene Therapies, Inc. is a gene therapy company that develops and commercializes adeno-associated virus-based treatments for monogenic central nervous system diseases, with a market cap of $334.15 million.

Operations: The company's revenue segment is entirely derived from developing adeno-associated virus-based gene therapies for the treatment of rare monogenic diseases, totaling $8.33 million.

Market Cap: $334.15M

Taysha Gene Therapies, with a market cap of US$334.15 million, is currently unprofitable and pre-revenue, focusing on developing gene therapies for rare diseases. Despite a decline in sales from US$15.45 million to US$8.33 million year-over-year, the company reduced its net loss from US$111.57 million to US$89.3 million in 2024. Taysha has more cash than debt and its short-term assets exceed liabilities, providing some financial stability amid ongoing losses and increased debt-to-equity ratio over five years. The company filed shelf registrations totaling over $326 million recently and remains part of the S&P Biotechnology Select Industry Index.

• Dive into the specifics of Taysha Gene Therapies here with our thorough balance sheet health report.

• Assess Taysha Gene Therapies' future earnings estimates with our detailed growth reports.

Summing It All Up

• Access the full spectrum of 749 US Penny Stocks by clicking on this link.

• Have a stake in these businesses? Integrate your holdings into Simply Wall St's portfolio for notifications and detailed stock reports.

• Unlock the power of informed investing with Simply Wall St, your free guide to navigating stock markets worldwide.

Contemplating Other Strategies?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.

• Jump on the AI train with fast growing tech companies forging a new era of innovation.

• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include NasdaqCM:NNDM NasdaqGS:PRTS and NasdaqGS:TSHA.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com